0001437749-23-023661.txt : 20230814 0001437749-23-023661.hdr.sgml : 20230814 20230814160514 ACCESSION NUMBER: 0001437749-23-023661 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230814 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230814 DATE AS OF CHANGE: 20230814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ICAD INC CENTRAL INDEX KEY: 0000749660 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 020377419 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-09341 FILM NUMBER: 231169759 BUSINESS ADDRESS: STREET 1: 98 SPIT BROOK ROAD, SUITE 100 CITY: NASHUA STATE: NH ZIP: 03062 BUSINESS PHONE: 603-882-5200 MAIL ADDRESS: STREET 1: 98 SPIT BROOK ROAD, SUITE 100 CITY: NASHUA STATE: NH ZIP: 03062 FORMER COMPANY: FORMER CONFORMED NAME: HOWTEK INC DATE OF NAME CHANGE: 19920703 8-K 1 icad20230531_8k.htm FORM 8-K icad20230531_8k.htm
false 0000749660 0000749660 2023-08-14 2023-08-14
 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 

 
FORM 8-K
 

 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): August 14, 2023
 

 
iCAD, INC.
(Exact Name of Registrant as Specified in Its Charter)
 

 
Delaware
(State or Other Jurisdiction of Incorporation)
 
     
001-09341
 
02-0377419
(Commission
File Number)
 
(IRS Employer
Identification No.)
   
98 Spit Brook Road, Suite 100, Nashua, New Hampshire
 
03062
(Address of Principal Executive Offices)
 
(Zip Code)
 
(603) 882-5200
(Registrants Telephone Number, Including Area Code)
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading
symbol(s)
 
Name of each exchange
on which registered
Common Stock, $0.01 par value
 
ICAD
 
The Nasdaq Stock Market LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 


 

 
Item 2.02.
Results of Operations and Financial Condition
 
On August 14, 2023, iCAD, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
 
Item 9.01
Financial Statements and exhibit
 
Exhibits 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
 
(d) Exhibits
 
99.1
   
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
iCAD, INC.
(Registrant)
     
 
By:
/s/ Dana Brown
   
Dana Brown
Chief Executive Officer and President
 
Date: August 14, 2023
 
 
EX-99.1 2 ex_528268.htm EXHIBIT 99.1 ex_528268.htm

Exhibit 99.1

 

iCAD Reports Financial Results for Second Quarter Ended June 30, 2023 

 

Company to host conference call and webcast today at 4:30 PM ET 

 

NASHUA, N.H. – August 14, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and six months ended June 30, 2023

 

Highlights:

 

 

iCAD signs 20-year worldwide development and commercialization agreement with Google Health to integrate Google’s AI technology with its ProFound Detection for 2D Mammography for use upon regulatory approval as an independent reader for breast cancer screening.
 

iCAD signs strategic multi-year commercial agreement with Radiology Partners, the nation’s largest radiology practice providing 15% of all U.S. mammography screenings, through its owned and affiliated practice, enabling iCAD to expand access to the Company’s Breast AI Suite to thousands of physicians and millions of patients in the U.S. 
 

Company secures largest subscription deal to-date with a prestigious multispecialty academic medical center renowned for exceptional healthcare services and ranked as one of the top hospitals in the U.S.

  Company remains on track to achieve profitability exiting 2024 via implementation of a number of strategic changes to align and streamline cost base, while reducing annualized expenses by $4.3 - $4.6 million.

 

"We are pleased to report significant progress last quarter in our collaborations with some of our most esteemed partners, exemplifying our Company’s commitment to creating the world's most pervasive and personalized suite of AI cancer detection solutions for our shareholders and stakeholders,” said Dana Brown, President and CEO of iCAD, Inc. 

 

“Our continued collaboration with Google Health will expand the integration of their AI technology with iCAD's ProFound AI for 2D Mammography for use upon regulatory approval as an independent reader for breast cancer screening. This 20-year worldwide commercialization agreement offers the potential to ease radiologist workload around the globe, particularly in countries where a double-reading workflow is standard practice, while offering a viable solution to the global radiologist shortage that is continuing to impact patient care. With the majority of imaging facilities outside the US still using 2D mammography as the standard of care, this agreement expands and accelerates our ability to serve this market and revolutionize screening for millions of women around the world,” Ms. Brown said. 

 

"The finalization of our strategic multi-year commercial agreement with Radiology Partners also represents a momentous achievement for iCAD. Radiology Partners is a leading provider of mammography services to millions of women annually across more than 3,200 facilities in the U.S., including 17 of the 20 largest health systems in the country, and we are honored that Radiology Partners has selected iCAD as its provider of breast AI technologies. We are working closely with Radiology Partners and actively deploying iCAD's technology through Radiology Partners’ cloud to their network of facilities, significantly increasing the potential for adoption and driving improvements in mammography screening for countless women across the country. With an initial order from Radiology Partners recognized in 1Q 2023 and the execution of this agreement, we are enthusiastic about the potential of this relationship in 2023 and beyond,” said Ms. Brown. 

 

“We are also pleased to report our team successfully closed the biggest subscription deal in our company's history with a prestigious multispecialty academic medical center that is renowned for its exceptional healthcare services and ranked as one of the top hospitals in the nation. This collaboration not only reinforces our position as the trusted leader of mammography AI solutions but also demonstrates the widespread recognition of the value we bring to facilities, clinicians, and patients.”

 

"As we continue to focus on driving growth and efficiency, we remain committed to achieving profitability by the end of 2024. Our strategic changes to align and streamline our cost base, along with a targeted reduction in annualized expenses, are paving the way for a sustainable and successful future for iCAD."  

 

Three Months Ended June 30, 2023 Financial Results

 

Total Detection and Therapy revenue for the second quarter of 2023 was $5.9 million, a decrease of $1.7 million, or 23%, as compared to the second quarter of 2022.

 

(in 000’s)

 

Three months ended June 30,

 
   

2023

   

2022

   

$ Change

   

% Change

 

Product revenue

  $ 2,644     $ 4,475     $ (1,831 )     -40.9 %

Service and supplies revenue

    3,221       3,100       121       3.9 %

Total revenue

  $ 5,865     $ 7,575     $ (1,710 )     -22.6 %

 

Revenue: Cancer Detection revenue for the second quarter of 2023, which includes the Company’s mammography and breast density products, and the associated service and supplies revenue, was $4.2 million, a decrease of 21%, as compared to the second quarter of 2022. Therapy revenue for the second quarter of 2023, which includes Xoft® Axxent® eBx® System® sales, as well as the associated service and supplies revenue, was $1.7 million, a decrease of 26%, as compared to the second quarter of 2022.

 

(in 000’s)

 

Three months ended June 30,

 
   

2023

   

2022

   

$ Change

   

% Change

 

Detection revenue

                               

Product revenue

  $ 2,301     $ 3,467     $ (1,166 )     -33.6 %

Service and supplies revenue

    1,870       1,822       48       2.6 %

Detection revenue

  $ 4,171     $ 5,289     $ (1,118 )     -21.1 %

Therapy revenue

                               

Product revenue

  $ 343     $ 1,008     $ (665 )     -66.0 %

Service and supplies revenue

    1,351       1,278       73       5.7 %

Therapy revenue

  $ 1,694     $ 2,286     $ (592 )     -25.9 %

Total revenue

  $ 5,865     $ 7,575     $ (1,710 )     -22.6 %

 

Gross Profit: Gross profit for the second quarter of 2023 was $4.3 million, or 74% of revenue, as compared to $5.5 million, or 72% of revenue, in the second quarter of 2022.

 

Operating Expenses: Total operating expenses for the second quarter of 2023 were $6.3 million, a 27% decrease from $8.6 million in the second quarter of 2022.

 

GAAP Net Loss: Net loss for the second quarter of 2023 was ($1.8) million, or ($0.07) per diluted share, as compared to a net loss of ($3.1) million, or ($0.12) per diluted share, for the second quarter of 2022.

 

Non-GAAP Adjusted Net Loss: Non-GAAP Adjusted Net Loss, a non-GAAP financial measure as defined below, for the second quarter of 2023 was ($1.6) million, or ($0.07) per diluted share, as compared to a Non-GAAP Adjusted Net Loss of ($3.1) million, or ($0.12) per diluted share, for the second quarter of 2022. Please refer to the section entitled “Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures” and the accompanying financial table included at the end of this release for a reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss results for the three-month periods ended June 30, 2023 and 2022, respectively.

 

 

 

Non-GAAP Adjusted EBITDA: Non-GAAP Adjusted EBITDA, a non-GAAP financial measure as defined below, for the second quarter of 2023 was a loss of ($1.5) million compared to a loss of $(2.7) million in the second quarter of 2022. Please refer to the section entitled “Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures” and the accompanying financial table included at the end of this release for a reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA results for the three-month periods ended June 30, 2023 and 2022, respectively.  

 

Six Months Ended June 30, 2023 Financial Results

 

Total Detection and Therapy revenue for the six months ended June 30, 2023 was $11.6 million, a decrease of $3.5 million, or 23%, as compared to the six months ended June 30, 2022.

 

(in 000’s)

 

Six months ended June 30,

 
   

2023

   

2022

   

$ Change

   

% Change

 

Product revenue

  $ 5,387     $ 9,035     $ (3,648 )     -40.4 %

Service and supplies revenue

    6,256       6,063       193       3.2 %

Total revenue

  $ 11,643     $ 15,098     $ (3,455 )     -22.9 %

 

Revenue: Cancer Detection revenue for the six months ended June 30, 2023, which includes the Company’s mammography and breast density products, and the associated service and supplies revenue, was $8.5 million, a decrease of 21%, as compared to the six months ended June 30, 2022. Therapy revenue for the six months ended June 30, 2023, which includes Xoft® Axxent® eBx® System® sales, as well as the associated service and supplies revenue, was $3.1 million, a decrease of 27%, as compared to the six months ended June 30, 2022.

 

(in 000’s)

 

Six months ended June 30,

 
   

2023

   

2022

   

$ Change

   

% Change

 

Detection revenue

                               

Product revenue

  $ 4,762     $ 7,330     $ (2,568 )     -35.0 %

Service and supplies revenue

    3,744       3,479       265       7.6 %

Detection revenue

  $ 8,506     $ 10,809     $ (2,303 )     -21.3 %

Therapy revenue

                               

Product revenue

  $ 626     $ 1,705     $ (1,079 )     -63.3 %

Service and supplies revenue

    2,511       2,584       (73 )     -2.8 %

Therapy revenue

  $ 3,137     $ 4,289     $ (1,152 )     -26.9 %

Total revenue

  $ 11,643     $ 15,098     $ (3,455 )     -22.9 %

 

Gross Profit: Gross profit for the six months ended June 30, 2023 was $8.5 million, or 73% of revenue, as compared to $10.8 million, or 72% of revenue, for the six months ended June 30, 2022.

 

Operating Expenses: Total operating expenses for the six months ended June 30, 2023 were $14.3 million, an 18% decrease from $17.4 million for the six months ended June 30, 2022.

 

GAAP Net Loss: Net loss for the six months ended June 30, 2023 ($5.5) million, or ($0.22) per diluted share, as compared to a net loss of ($6.7) million, or ($0.26) per diluted share, for the six months ended June 30, 2022.

 

Non-GAAP Adjusted Net Loss: Non-GAAP Adjusted Net Loss, a non-GAAP financial measure as defined below, for the six months ended June 30, 2023 was ($5.4) million, or ($0.21) per diluted share, as compared to a Non-GAAP Adjusted Net Loss of ($6.7) million, or ($0.26) per diluted share, for the six months ended June 30, 2022.  Please refer to the section entitled “Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures” and the accompanying financial table included at the end of this release for a reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss results for the six-month periods ended June 30, 2023 and 2022, respectively.

 

 

 

Non-GAAP Adjusted EBITDA: Non-GAAP Adjusted EBITDA, a non-GAAP financial measure as defined below, for the first six months of 2023 was a loss of ($4.6) million compared to a loss of $(5.4) million in the first six months of 2022. Please refer to the section entitled “Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures” and the accompanying financial table included at the end of this release for a reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA results for the six-month periods ended June 30, 2023 and 2022, respectively. 

 

Conference Call

Monday, August 14 at 4:30 PM ET 

 

     

Domestic:

 

888-506-0062

International:

 

973-528-0011

Conference ID:

 

460678

Webcast:

  https://www.webcaster4.com/Webcast/Page/2879/48562

 

Use of Non-GAAP Financial Measures

 

In its quarterly news releases, conference calls, slide presentations or webcasts, the Company may use or discuss non-GAAP financial measures as defined by SEC Regulation G. The GAAP financial measures most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. When analyzing the Company’s operating performance, investors should not consider these non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP. The Company’s quarterly news releases containing such non-GAAP reconciliations can be found on the Investors section of the Company’s website at www.icadmed.com.

 

About iCAD, Inc.

 

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.

 

Forward-Looking Statements       

                              

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov. 

 

 

 

Media Inquiries:

 

Jessica Burns, iCAD

+1-201-423-4492

jburns@icadmed.com

 

Investor Inquiries:

 

iCAD Investor Relations

ir@icadmed.com

 

 

 

iCAD, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(In thousands, except for share data)

(Unaudited)

 

   

June 30,

   

December 31,

 
   

2023

   

2022

 

Assets

               

Current assets:

               

Cash and cash equivalents

  $ 19,037     $ 21,313  

Trade accounts receivable, net of allowances for credit losses of $984 and $922 as of June 30, 2023 and December 31, 2022 respectively

    5,747       8,898  

Inventory, net

    4,248       5,389  

Prepaid expenses and other current assets

    2,304       2,641  

Total current assets

    31,336       38,241  

Property and equipment, net of accumulated depreciation of $2,273 and 2,135 as of June 30, 2023 and December 31, 2022, respectively

    1,471       1,074  

Operating lease assets

    3,113       3,361  

Other assets

    54       69  

Intangible assets, net of accumulated amortization of $8,490 and $8,932 as of June 30, 2023 and December 31, 2022, respectively

    388       482  

Goodwill

    8,362       8,362  

Deferred tax assets

    108       116  

Total assets

  $ 44,832     $ 51,705  

Liabilities and Stockholders’ Equity

               

Current liabilities:

               

Accounts payable

  $ 857     $ 1,973  

Accrued and other expenses

    4,363       4,681  

Lease payable—current portion

    644       582  

Deferred revenue—current portion

    6,027       6,216  

Total current liabilities

    11,891       13,452  

Lease payable, net of current

    2,478       2,803  

Deferred revenue, net of current

    283       542  

Deferred tax

    6       6  

Total liabilities

    14,658       16,803  

Commitments and Contingencies

               

Stockholders’ equity:

               

Preferred stock, $0.01 par value: authorized 1,000,000 shares; none issued.

           
                 

Common stock, $0.01 par value: authorized 60,000,000 shares; issued 25,446,578 as of both June 30, 2023 and December 31, 2022; outstanding 25,260,576 as of both June 30, 2023 and December 31, 2022

    254       254  

Additional paid-in capital

    303,699       302,899  

Accumulated deficit

    (272,364 )     (266,836 )

Treasury stock at cost, 185,831 shares as of both June 30, 2023 and December 31, 2022

    (1,415 )     (1,415 )

Total stockholders’ equity

    30,174       34,902  

Total liabilities and stockholders’ equity

  $ 44,832     $ 51,705  

 

 

 

iCAD, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(In thousands, except for per share data)

(Unaudited)

 

   

Three Months Ended

   

Six Months Ended

 
   

June 30,

   

June 30,

 
   

2023

   

2022

   

2023

   

2022

 

Revenue:

                               

Products

  $ 2,644     $ 4,475     $ 5,387     $ 9,035  

Service and supplies

    3,221       3,100       6,256       6,063  

Total revenue

    5,865       7,575       11,643       15,098  

Cost of revenue:

                               

Products

    461       1,008       1,047       2,095  

Service and supplies

    1,000       1,001       1,993       2,050  

Amortization and depreciation

    55       75       125       150  

Total cost of revenue

    1,516       2,084       3,165       4,295  

Gross profit

    4,349       5,491       8,478       10,803  

Operating expenses:

                               

Engineering and product development

    1,263       2,367       3,544       4,642  

Marketing and sales

    2,112       3,435       4,967       7,000  

General and administrative

    2,832       2,742       5,695       5,673  

Amortization and depreciation

    65       61       120       124  

Total operating expenses

    6,272       8,605       14,326       17,439  

Loss from operations

    (1,923 )     (3,114 )     (5,848 )     (6,636 )

Other income/ (expense):

                               

Interest expense

                      (1 )

Interest income

    182       14       332       16  

Other income (expense), net

    (5 )     (18 )     (3 )     (41 )

Other income (expense), net

    177       (4 )     329       (26 )

Loss before provision for income taxes

    (1,746 )     (3,118 )     (5,519 )     (6,662 )

Benefit (Provision) for tax expense

    (4 )           (9 )     (1 )

Net loss and comprehensive loss

  $ (1,750 )   $ (3,118 )   $ (5,528 )   $ (6,663 )

Net loss per share:

                               

Basic and diluted

  $ (0.07 )   $ (0.12 )   $ (0.22 )   $ (0.26 )

Weighted average number of shares used in computing loss per share:

    25,261       25,185       25,261       25,172  

 

 

 

iCAD, INC. AND SUBSIDIARIES

 

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

   

For the Six Months ended

 
   

June 30,

 
   

2023

   

2022

 

Cash flow from operating activities:

               

Net loss

  $ (5,528 )   $ (6,663 )

Adjustments to reconcile net loss to net cash used for operating activities:

               

Amortization

    94       105  

Depreciation

    138       169  

Non-cash lease expense

    248       391  

Bad debt provision

    62       510  

Stock-based compensation

    800       964  

Deferred tax

    8        

Changes in operating assets and liabilities:

               

Accounts receivable

    3,089       (1,790 )

Inventory

    1,141       (830 )

Prepaid and other assets

    352       853  

Accounts payable

    (1,116 )     (581 )

Accrued and other expenses

    (510 )     (371 )

Lease liabilities

    (263 )     (425 )

Deferred revenue

    (448 )     659  

Total adjustments

    3,595       (346 )

Net cash used for operating activities

    (1,933 )     (7,009 )

Cash flow from investing activities:

               

Additions to patents, technology and other

          (10 )

Additions to property and equipment

    (307 )     (255 )

Capitalization of internal-use software

    (36 )      

Net cash used for investing activities

    (343 )     (265 )

Cash flow from financing activities:

               

Proceeds from option exercises pursuant to stock option plans

          79  

Proceeds from issuance of common stock pursuant to Employee Stock Purchase Plans

          93  

Net cash provided by financing activities

          172  

(Decrease) increase in cash and cash equivalents

    (2,276 )     (7,102 )

Cash and cash equivalents, beginning of period

    21,313       34,282  

Cash and cash equivalents, end of period

  $ 19,037     $ 27,180  

Supplemental disclosure of cash flow information:

               

Interest paid

   

$ —

     

$ 9

 

Amendment to right-of-use assets obtained in exchange for operating lease liabilities

   

$ 2,434

         

 

 

 

 

 

Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures

 

The Company reports its financial results in accordance with United States generally accepted accounting principles, or GAAP. However, management believes that in order to understand the Company’s short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP. These items result from facts and circumstances that vary in frequency and/or impact on continuing operations. Management also uses results of operations before such items to evaluate the operating performance of the Company and compare it against past periods, make operating decisions, and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in the Company’s ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of the Company’s ongoing business with prior periods more difficult, obscure trends in ongoing operations or reduce management’s ability to make useful forecasts. Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing the Company’s financial and operational performance and comparing this performance to its peers and competitors.

 

Management defines “Non-GAAP Adjusted EBITDA” as the sum of GAAP Net Loss before provisions for interest expense, other income, stock-based compensation expense, depreciation and amortization, tax expense, severance, gain on sale of assets, loss on disposal of assets, acquisition and litigation related expenses. Management considers this non-GAAP financial measure to be an indicator of the Company’s operational strength and performance of its business and a good measure of its historical operating trends, in particular the extent to which ongoing operations impact the Company’s overall financial performance.

 

The non-GAAP financial measures do not replace the presentation of the Company’s GAAP financial results and should only be used as a supplement to, not as a substitute for, the Company’s financial results presented in accordance with GAAP. The Company has provided a reconciliation of each non-GAAP financial measure used in its financial reporting and investor presentations to the most directly comparable GAAP financial measure.

 

Management excludes each of the items identified below from the applicable non-GAAP financial measure referenced above for the reasons set forth with respect to that excluded item:

 

 

Interest expense: The Company excludes interest expense which includes interest from the facility agreement, interest on capital leases and interest on the convertible debentures from its non-GAAP Adjusted EBITDA calculation.

 

 

Stock-based compensation expense: excluded as these are non-cash expenses that management does not consider part of ongoing operating results when assessing the performance of the Company’s business, and also because the total amount of expense is partially outside of the Company’s control as it is based on factors such as stock price volatility and interest rates, which may be unrelated to our performance during the period in which the expense is incurred.

 

 

Amortization and Depreciation: Purchased assets and intangibles are amortized over a period of several years and generally cannot be changed or influenced by management after they are acquired. Accordingly, these non-cash items are not considered by management in making operating decisions, and management believes that such expenses do not have a direct correlation to future business operations. Thus, including such charges does not accurately reflect the performance of the Company’s ongoing operations for the period in which such charges are incurred.

 

 

Severance and Furlough: The Company has incurred severance and furlough expenses in connection with restructuring and in connection with the separation of its former CEO.  The Company excludes these items from its non-GAAP financial measures when evaluating its continuing business performance as such items can vary significantly and do not reflect expected future operating expenses. In addition, management believes that such items do not have a direct correlation to future business operations.   

 

 

Loss on fair value of convertible debentures. The Company excludes this non-cash item as it is not considered by management in making operating decisions, and management believes that such item does not have a direct correlation to future business operations.

 

 

Litigation related: These expenses consist primarily of settlement, legal and other professional fees related to litigation. The Company excludes these costs from its non-GAAP measures primarily because the Company believes that these costs have no direct correlation to the core operations of the Company.

 

 

Loss on extinguishment of debt: The Company excludes this non-cash item as it is not considered by management in making operating decisions, and management believes that such item does not have a direct correlation to future business operations.

 

On occasion in the future, there may be other items, such as loss on extinguishment of debt, significant asset impairments, restructuring charges or significant gains or losses from contingencies that the Company may exclude if it believes that doing so is consistent with the goal of providing useful information to investors and management.

 

 

 

Non-GAAP Adjusted EBITDA

Set forth below is a reconciliation of the Company’s “Non-GAAP Adjusted EBITDA”

(Unaudited)

(In thousands except for per share data)

 

   

Three Months Ended June 30,

   

Six Months Ended June 30,

 
   

2023

   

2022

   

2023

   

2022

 

GAAP Net Loss

  $ (1,750 )   $ (3,118 )   $ (5,528 )   $ (6,663 )

Interest expense

                      1  

Interest income

    (182 )     (14 )     (332 )     (16 )

Other expense

    5       18       3       41  

Stock compensation

    214       309       800       964  

Depreciation & amortization

    117       137       232       274  

Severance and Furlough

    102             178        

Tax expense

    4             9       1  

Non-GAAP Adjusted EBITDA

  $ (1,490 )   $ (2,668 )   $ (4,638 )   $ (5,398 )

 

   

Three Months Ended June 30,

   

Six Months Ended June 30,

 
   

2023

   

2022

   

2023

   

2022

 

GAAP Net Loss

  $ (1,750 )   $ (3,118 )   $ (5,528 )   $ (6,663 )

Adjustments to Net Loss:

                               

Severance and Furlough

    102             178        

Non-GAAP Adjusted Net Loss

  $ (1,648 )   $ (3,118 )   $ (5,350 )   $ (6,663 )

Net Loss per share—basic and diluted

                               

GAAP Net Loss per share

  $ (0.07 )   $ (0.12 )   $ (0.22 )   $ (0.26 )

Adjustments to Net Loss (as detailed above)

                0.01        

Non-GAAP Adjusted Net Loss per share

  $ (0.07 )   $ (0.12 )   $ (0.21 )   $ (0.26 )

 

 

 
EX-101.SCH 3 icad-20230814.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 icad-20230814_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 icad-20230814_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 icad-20230814_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document And Entity Information
Aug. 14, 2023
Document Information [Line Items]  
Entity, Registrant Name iCAD, INC.
Document, Type 8-K
Document, Period End Date Aug. 14, 2023
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-09341
Entity, Tax Identification Number 02-0377419
Entity, Address, Address Line One 98 Spit Brook Road, Suite 100
Entity, Address, City or Town Nashua
Entity, Address, State or Province NH
Entity, Address, Postal Zip Code 03062
City Area Code 603
Local Phone Number 882-5200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ICAD
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0000749660
XML 8 icad20230531_8k_htm.xml IDEA: XBRL DOCUMENT 0000749660 2023-08-14 2023-08-14 false 0000749660 8-K 2023-08-14 iCAD, INC. DE 001-09341 02-0377419 98 Spit Brook Road, Suite 100 Nashua NH 03062 603 882-5200 false false false false Common Stock ICAD NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "E@ Y799!YDAD! #/ M P $P @ &9$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 1 "0 ) #X" #C$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.icad.com/20230814/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports icad20230531_8k.htm ex_528268.htm icad-20230814.xsd icad-20230814_def.xml icad-20230814_lab.xml icad-20230814_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "icad20230531_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "icad-20230814_def.xml" ] }, "inline": { "local": [ "icad20230531_8k.htm" ] }, "labelLink": { "local": [ "icad-20230814_lab.xml" ] }, "presentationLink": { "local": [ "icad-20230814_pre.xml" ] }, "schema": { "local": [ "icad-20230814.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "icad", "nsuri": "http://www.icad.com/20230814", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "icad20230531_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.icad.com/20230814/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "icad20230531_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.icad.com/20230814/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001437749-23-023661-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-023661-xbrl.zip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end